Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104390 · ClinicalTrials.gov registry record · Phase 1
Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
A Phase 1 study of Type I Hypersensitivity, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00104390 is a Phase 1 study of Type I Hypersensitivity that has completed, run by Allergy Therapeutics. The registered enrollment target is 14 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00104390, a Phase 1 study of Type I Hypersensitivity, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the residual allergenicity of Grass MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing. This is done by a comparison of the wheal response after skin prick testing with aqueous native and modified allergen, modified tyrosine adsorbed allergen and Grass MATA MPL (modified tyrosine adsorbed + MPL).
Conditions Studied
Interventions
- BIOLOGICAL Grass MATA MPL
Study Locations (1)
Oregon
- Allergy Associates Research Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104390
The ClinicalTrials.gov registry entry for NCT00104390 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergy Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type I Hypersensitivity appearing as the primary indexed condition, and to 1 intervention - of which Grass MATA MPL is the first listed.
NCT00104390 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT00104390 about?
NCT00104390 is a clinical study titled "Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing". The purpose of this study is to evaluate the residual allergenicity of Grass MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing. This is done by a comparison of the wheal response after skin prick testing with aqueous native and modified allergen, modified tyrosine adsorbed all...
What is the current status of trial NCT00104390?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2005-03. Estimated completion is 2005-04.
What conditions does trial NCT00104390 study?
This clinical trial studies the following conditions: Type I Hypersensitivity.
What interventions are being tested in trial NCT00104390?
The interventions under investigation include: Grass MATA MPL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00104390?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104390 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type I Hypersensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.